Upgrade to SI Premium - Free Trial

Vanda reports positive Phase III results for HETLIOZ in sleep disorder

September 29, 2026 7:10 PM
Vanda Pharmaceuticals (NASDAQ: VNDA) announced positive topline results from a Phase III study of HETLIOZ (tasimelteon) 20 mg in adults ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA

Next Articles